Statistics

  • An estimated amount of 10% to 30% of patients who posses acute aortic syndrome encounter intramural hematoma (IMH) (1)
  • The majority of patients who have IMH have Stanford type B (50%-85%)
    • Type B – *Exclusive involvement of the descending aorta* (1)
  • Some non-traumatic causes including conditions such as penetrating aortic ulcer (PAU) (1)
  • The risk of developing such complications including pocket hematomas during and after CIED implantation increases to 14% including pre-existing thrombocytopenia and heparin bridging therapy and to 16.2% through dual antiplatelet therapy (DAP) (2)
  • They are one of the most common complications of CIED implants.
    • Pocket hematomas are associated with increased risk of mortality, longer stays in the hospital (3.6 days) and heightened medical costs (21%). (2)
  • Pocket hematomas cause about 25% of early re-operations in patients with CIED implants (3).

Images:

Kutinsky, Ilana B., et al. “Risk of Hematoma Complications after Device Implant in the Clopidogrel Era.” Circulation: Arrhythmia and Electrophysiology, 17 June 2010, http://www.ahajournals.org/doi/10.1161/circep.109.917625.%5B/caption%5D

 

 

 

Citations: